CA2333657A1 - Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders - Google Patents
Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders Download PDFInfo
- Publication number
- CA2333657A1 CA2333657A1 CA002333657A CA2333657A CA2333657A1 CA 2333657 A1 CA2333657 A1 CA 2333657A1 CA 002333657 A CA002333657 A CA 002333657A CA 2333657 A CA2333657 A CA 2333657A CA 2333657 A1 CA2333657 A1 CA 2333657A1
- Authority
- CA
- Canada
- Prior art keywords
- secretin
- effective amount
- individual
- disorder
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 title claims abstract description 131
- 108010086019 Secretin Proteins 0.000 title claims abstract description 128
- 102100037505 Secretin Human genes 0.000 title claims abstract description 128
- 229960002101 secretin Drugs 0.000 title claims abstract description 128
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 230000000926 neurological effect Effects 0.000 title claims abstract description 16
- 208000026278 immune system disease Diseases 0.000 title claims abstract description 14
- 208000020706 Autistic disease Diseases 0.000 title claims description 26
- 206010003805 Autism Diseases 0.000 title claims description 25
- 230000003542 behavioural effect Effects 0.000 title abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims abstract description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 28
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 20
- 208000012902 Nervous system disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000001802 infusion Methods 0.000 claims description 14
- 208000024891 symptom Diseases 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- 230000028327 secretion Effects 0.000 claims description 11
- 210000001819 pancreatic juice Anatomy 0.000 claims description 10
- 229940076279 serotonin Drugs 0.000 claims description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 7
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 5
- 229960003638 dopamine Drugs 0.000 claims description 4
- 210000001198 duodenum Anatomy 0.000 claims description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 208000022531 anorexia Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 206010061428 decreased appetite Diseases 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 239000012466 permeate Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 208000032841 Bulimia Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 239000002858 neurotransmitter agent Substances 0.000 description 8
- 208000025966 Neurological disease Diseases 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 6
- 101800001982 Cholecystokinin Proteins 0.000 description 4
- 102100025841 Cholecystokinin Human genes 0.000 description 4
- 208000012202 Pervasive developmental disease Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000013404 behavioral symptom Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940107137 cholecystokinin Drugs 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 201000005404 rubella Diseases 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 201000005505 Measles Diseases 0.000 description 3
- 208000005647 Mumps Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000010805 mumps infectious disease Diseases 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010093625 Opioid Peptides Proteins 0.000 description 2
- 102000001490 Opioid Peptides Human genes 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- -1 but not limited to Chemical compound 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000003399 opiate peptide Substances 0.000 description 2
- 230000001936 parietal effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 210000003478 temporal lobe Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000004240 Triticum spelta Nutrition 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000015228 chicken nuggets Nutrition 0.000 description 1
- 230000008131 children development Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 235000012020 french fries Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000006171 gluten free diet Nutrition 0.000 description 1
- 235000020884 gluten-free diet Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007230 neural mechanism Effects 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8857598P | 1998-06-09 | 1998-06-09 | |
| US60/088,575 | 1998-06-09 | ||
| US09/229,208 US6197746B1 (en) | 1998-05-19 | 1999-01-13 | Method of using secretin for treating autism |
| US09/229,208 | 1999-01-13 | ||
| PCT/US1999/013061 WO1999064059A2 (en) | 1998-06-09 | 1999-06-09 | Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2333657A1 true CA2333657A1 (en) | 1999-12-16 |
Family
ID=26778819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002333657A Abandoned CA2333657A1 (en) | 1998-06-09 | 1999-06-09 | Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6197746B1 (enExample) |
| EP (1) | EP1085901B1 (enExample) |
| JP (1) | JP2002517467A (enExample) |
| AT (1) | ATE322283T1 (enExample) |
| AU (1) | AU772911B2 (enExample) |
| CA (1) | CA2333657A1 (enExample) |
| DE (1) | DE69930739D1 (enExample) |
| WO (1) | WO1999064059A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020310A (en) * | 1997-05-19 | 2000-02-01 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
| US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| US6020314A (en) * | 1998-08-11 | 2000-02-01 | Milkhaus Laboratory, Inc. | Methods for treatment of neurological disorders |
| AU1779301A (en) * | 1999-11-22 | 2001-06-04 | Joseph A. Rogoff | Secretin and secretin pharmaceuticals for treating attention deficit disorder |
| US6632429B1 (en) * | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US6534063B1 (en) | 1999-12-17 | 2003-03-18 | Joan M. Fallon | Methods for treating pervasive development disorders |
| GB0008326D0 (en) * | 2000-04-06 | 2000-05-24 | Shs International Ltd | Diagnosis and treatment of autism and related disorders |
| GB0016441D0 (en) | 2000-07-04 | 2000-08-23 | Pharmagene Lab Limited | Therapeutic method |
| US6660831B2 (en) * | 2000-08-14 | 2003-12-09 | Joan M. Fallon | Method for diagnosing and treating dysautonomia and other dysautonomic conditions |
| US20070053895A1 (en) | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
| DK1486205T3 (da) * | 2000-08-25 | 2008-02-18 | Res Corp Technologies Inc | Anvendelse af antikonvulsive aminosyrer til behandling af migræne |
| US8030002B2 (en) * | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| GB0118383D0 (en) * | 2001-07-27 | 2001-09-19 | Pharmagene Lab Ltd | Therapeutic methods |
| US6585996B1 (en) | 2002-03-13 | 2003-07-01 | Westlake Laboratories, Inc. | Lipid-soluble thiamine derivatives in the treatment of autism |
| US8100844B2 (en) * | 2002-04-25 | 2012-01-24 | Ultraflex Systems, Inc. | Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint |
| US20070154534A1 (en) * | 2003-03-12 | 2007-07-05 | Sheitman Brian B | Use of secretin in the treatment of schizophrenia |
| US20050002922A1 (en) * | 2003-03-12 | 2005-01-06 | Richard Boismenu | Use of secretin and secretin analogs to treat affective disorders |
| US8524665B2 (en) * | 2003-05-13 | 2013-09-03 | The Mclean Hospital Corporation | Use of secretin in treatments of disorders associated with the amygdala |
| US7947285B2 (en) * | 2003-12-12 | 2011-05-24 | Fein Seymour H | Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis |
| US7381698B2 (en) * | 2003-12-12 | 2008-06-03 | Chirhoclin, Inc. | Methods for treatment of acute pancreatitis |
| US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
| GB0504096D0 (en) * | 2005-02-28 | 2005-04-06 | Tipogen As | Method |
| US20070034214A1 (en) * | 2005-08-12 | 2007-02-15 | Dochniak Michael J | Method to affect the development of autism spectrum disorders |
| US20080058282A1 (en) * | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
| US8658163B2 (en) * | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| US9320780B2 (en) * | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| US20090324730A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
| EP2318035B1 (en) * | 2008-07-01 | 2019-06-12 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US10776453B2 (en) * | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| KR101694931B1 (ko) | 2009-01-06 | 2017-01-10 | 큐어론 엘엘씨 | 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법 |
| EP3064217B1 (en) | 2009-01-06 | 2018-04-18 | Galenagen, LLC | Compositions comprising protease, amylase and lipase for use in the treatment of staphylococcus aureus infections |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| CA2774963A1 (en) * | 2009-10-09 | 2011-04-14 | Prothera, Inc. | Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease |
| WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
| EP2552200B1 (en) * | 2010-03-31 | 2015-10-14 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (dmso) formulations for treating autism |
| US8962042B2 (en) | 2010-09-28 | 2015-02-24 | Lisa Geng | Methods for treating neurological disorders using nutrient compositions |
| US9931365B2 (en) | 2010-09-28 | 2018-04-03 | Lisa Geng | Methods for treating neurological disorders using nutrient compositions |
| MX347770B (es) | 2011-04-21 | 2017-05-12 | Curemark Llc | Compuesto para el tratamiento de alteraciones neuropsiquiatricas. |
| US9442092B2 (en) | 2011-06-20 | 2016-09-13 | Kerry Lane | Methods for treatment of autism |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| US12226464B2 (en) | 2017-04-10 | 2025-02-18 | Curemark, Llc | Compositions for treating addiction |
| US11318190B2 (en) | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
| CN109908120B (zh) * | 2019-04-22 | 2022-04-19 | 井冈山大学 | 一种狭顶鳞毛蕨有效成分、提取方法及其应用 |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833722A (en) | 1971-03-16 | 1974-09-03 | D Graybill | Method for controlling allergies |
| JPS5029005B2 (enExample) * | 1972-05-08 | 1975-09-19 | ||
| US3987014A (en) | 1974-01-10 | 1976-10-19 | Becton, Dickinson And Company | Secretin intermediates and derivatives |
| DE2615229C2 (de) | 1976-04-08 | 1984-05-24 | Hoechst Ag, 6230 Frankfurt | Verfahren zur Herstellung und Reinigung von Sekretin |
| US4086220A (en) | 1976-08-09 | 1978-04-25 | G. D. Searle & Co. | Fragments of secretin |
| DE3066483D1 (en) | 1979-06-13 | 1984-03-15 | Hoechst Ag | Pharmaceutical compositions based on secretin with enhanced and protracted activity, process for their preparation and dihydroxybenzoyl-l-tyrosine |
| NZ196349A (en) | 1980-03-07 | 1984-08-24 | Interx Research Corp | Enhancement of absorption rate of orally administered polar bioactive agents |
| JPS58140024A (ja) | 1982-02-15 | 1983-08-19 | Eisai Co Ltd | セクレチンの精製方法 |
| DE3328793A1 (de) | 1983-08-10 | 1985-02-28 | Hoechst Ag, 6230 Frankfurt | Herstellung von sekretin |
| SE454513B (sv) | 1985-03-11 | 1988-05-09 | Kabigen Ab | Humant sekretin samt kompositioner innehallande detta |
| JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
| US5008251A (en) | 1986-03-27 | 1991-04-16 | The Regents Of The University Of California | Method of treating autism |
| US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| US5094837A (en) | 1990-01-22 | 1992-03-10 | Wayne State University | Method for use of magnetic resonance imaging to image pancreas using secretin |
| US5225407A (en) | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
| US5380872A (en) * | 1992-07-14 | 1995-01-10 | Glaxo Inc. | Modulators of cholecystokinin |
| DE69426415T2 (de) | 1993-01-29 | 2001-07-26 | Aradigm Corp., Hayward | Intrapulmonares hormonabgabesystem |
| US5527825A (en) | 1994-04-06 | 1996-06-18 | University Of Arkansas | Method of treating schizophrenia, tourette's syndrome, mania, autism, and obsessive compulsive disorder with inhibitors of brain nitric oxide synthase |
| US5560910A (en) * | 1994-08-26 | 1996-10-01 | Crandall; Wilson T. | Topical anti-inflammatory composition and method |
| GB9417524D0 (en) | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
| US5686311A (en) | 1995-06-23 | 1997-11-11 | The Children's Mercy Hospital | Diagnosis of autism and treatment therefor |
| US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| US6020310A (en) * | 1997-05-19 | 2000-02-01 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
| JP2001526881A (ja) | 1997-09-11 | 2001-12-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 染色体会合に必要とされるプラス端指向性微小管モーター |
-
1999
- 1999-01-13 US US09/229,208 patent/US6197746B1/en not_active Expired - Fee Related
- 1999-06-09 WO PCT/US1999/013061 patent/WO1999064059A2/en not_active Ceased
- 1999-06-09 JP JP2000553127A patent/JP2002517467A/ja not_active Withdrawn
- 1999-06-09 CA CA002333657A patent/CA2333657A1/en not_active Abandoned
- 1999-06-09 AU AU44322/99A patent/AU772911B2/en not_active Ceased
- 1999-06-09 EP EP99927416A patent/EP1085901B1/en not_active Expired - Lifetime
- 1999-06-09 DE DE69930739T patent/DE69930739D1/de not_active Expired - Lifetime
- 1999-06-09 AT AT99927416T patent/ATE322283T1/de not_active IP Right Cessation
-
2001
- 2001-03-05 US US09/800,431 patent/US6790825B2/en not_active Expired - Fee Related
-
2003
- 2003-08-08 US US10/637,250 patent/US20050249714A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU772911B2 (en) | 2004-05-13 |
| EP1085901A2 (en) | 2001-03-28 |
| DE69930739D1 (de) | 2006-05-18 |
| EP1085901B1 (en) | 2006-04-05 |
| US20010049353A1 (en) | 2001-12-06 |
| AU4432299A (en) | 1999-12-30 |
| US6790825B2 (en) | 2004-09-14 |
| US20050249714A1 (en) | 2005-11-10 |
| ATE322283T1 (de) | 2006-04-15 |
| US6197746B1 (en) | 2001-03-06 |
| WO1999064059A2 (en) | 1999-12-16 |
| JP2002517467A (ja) | 2002-06-18 |
| WO1999064059A3 (en) | 2000-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU772911B2 (en) | Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders | |
| Fernandez-Alvarez et al. | Movement disorders in children | |
| JP2014506254A (ja) | β−ヒドロキシ−β−メチルブチレートを用いる廃用期間後の筋肉回復を促進させるための方法 | |
| Aird et al. | Anticonvulsive properties of desoxycorticosterone | |
| JP2002501616A (ja) | 自閉的症候群を鑑別診断および治療する際の助けとするための方法 | |
| Dropcho et al. | Paraneoplastic opsoclonus-myoclonus: association with medullary thyroid carcinoma and review of the literature | |
| CN1711101A (zh) | 孤独症及相似障碍的治疗 | |
| EA013591B1 (ru) | Применение пептидных соединений для профилактики, облегчения и лечения головной боли и болезненных состояний, связанных с или вызванных распространяющейся кортикальной депрессией (csd) | |
| US20100168053A1 (en) | Oral delivery system for methylcobalamin to treat disorders | |
| Clavel et al. | Helping people to stop smoking: randomised comparison of groups being treated with acupuncture and nicotine gum with control group | |
| RU2195297C2 (ru) | Способ лечения дистрофических заболеваний глаз | |
| US11564958B2 (en) | Compositions and methods of treatment of Ehlers-Danlos syndromes | |
| CN114306207A (zh) | 一种以棒棒糖为载体的口腔给药方法 | |
| RU2709614C1 (ru) | Способ лечения энцефалопатии | |
| Restivo et al. | Trismus after stroke/TBI: botulinum toxin benefit and use pre-PEG placement | |
| RU2153891C2 (ru) | Способ лечения эпилепсии у детей | |
| Helms et al. | 12 Movement Disorders That Imitate Epilepsy | |
| RU2219936C2 (ru) | Способ лечения хронического слухового галлюциноза, резистентного к терапии | |
| WAGENER | Diseases of the retina and optic nerve | |
| Frucht et al. | Unusual Movement Disorders | |
| Vasylieva et al. | Study guide for individual preparation of “Physiology”(training tests of license exam “Krok 1”): manual for students of medical and dental faculty | |
| Fagan et al. | Pediatric neurologic potpourri: cases to remember | |
| RU2548712C2 (ru) | Способ лечения эпилепсий | |
| Harris | A Note On Vitamins In Practical Experience | |
| Fumigation et al. | AMA Arch. Indus!. Hyg. & Occup. Med., Chicago |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |